All that the company can say is that it has a paper in the process.
I think they could indicate more clearly where in the process it is. The PR for the Fiscal 2023 Year End Update said, "Full data from the blarcamesine in Alzheimer’s disease Phase 2b/3 randomized clinical trial will be published in an upcoming peer-reviewed journal." I took that to mean the paper had been accepted, which I think is a proper interpretation of "will be published." Subsequently the company said something about having no control over the peer-review process -- not "no control over the journal's timing of the publication date" -- which leads me to believe it hasn't yet been accepted.
I wish the company were more precise in matters like these.
The other recent example of this is the company's handling of where it is in the EMA process. I remain uncertain as to whether it has submitted the Letter of Intent or completed only the preceding step, which is the Submission of Eligibility. There's even been a statement or two from the company -- I'm getting this off the board, not directly from Anavex, so caveat emptor -- that could be interpreted to mean the MAA had been filed, though it was not as definitive-sounding as "will be published."
This trial has a lot of moving parts and since the condition has a lot of interested parties those reviewing the trial results I suspect are being extra careful knowing they will be subject to withering attacks by those promoting alternative therapies. All ducks in a row with a bow on top.
News 
Market Data 
Discover 
